How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

667 results for

stroke rehabilitation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

661. Management of stable angina

) • History of congestive heart failure • History of cerebrovascular disease • Preoperative insulin treatment • Preoperative creatinine >180 micromol/l. High-risk surgery is defined as intraperitoneal, intrathoracic, or suprainguinal vascular procedures. A history of IHD is defined as any of the following: a history of MI, positive exercise tolerance test, current complaint of chest pain of ischaemic origin, use of nitrate therapy or pathological Q waves on ECG. Patients with prior revascularisation (...) to prevent new vascular events 17 4.4 Medication concordance 18 5 Interventional cardiology and cardiac surgery 19 5.1 Coronary artery anatomy and definitions 19 5.2 Percutaneous coronary intervention 19 5.3 Coronary artery bypass grafting 21 5.4 Choice of revascularisation technique 23 5.5 Postintervention drug therapy 26 5.6 Postintervention rehabilitation 28 5.7 Managing restenosis 28 5.8 Managing refractory angina 28 6 Stable angina and non-cardiac surgery 30 6.1 Assessment prior to surgery 30 6.2

2018 SIGN

662. Cardiac arrhythmias in coronary heart disease

of trials in adults with or at high risk of CVD, no clear effect from omega-3 fatty acids was reported on composite cardiovascular outcomes (RR 0.96, 95% CI 0.90 to 1.03), total mortality (RR 0.95, 95% CI 0.86 to 1.04), non-vascular mortality (RR 0.97, 95% CI 0.84 to 1.11), coronary events (RR 0.86, 95% CI, 0.67 to 1.11) or revascularisation (RR 0.95, 95% CI 0.89 to 1.00). There was also no evidence of benefit for cerebrovascular events (RR 1.03, 95% CI 0.92 to 1.16) or arrhythmia (RR 0.99, 95% CI 0.85 (...) of ischaemic VT induced at electrophysiological study, sudden death and out-of-hospital collapse. R Revascularisation should be considered in patients who have had sustained VT or VF. 9 Patients with previous sustained VT/VF should undergo assessment for inducible ischaemia by stress testing or myocardial perfusion imaging followed, if appropriate, by coronary arteriography and revascularisation. These patients should all be considered for implantable cardioverter defibrillator therapy. 5.2.2 IMPLANTABLE

2018 SIGN

663. Management of chronic pain

risk of myocardial infarction and coronary heart disease death whereas this has not been observed with naproxen. In the same meta-analysis, all NSAIDs were associated with an increased risk of heart failure, but there was no evidence of an increased risk of stroke. 62 B NSAIDs should be considered in the treatment of patients with chronic non-specific low back pain. B Cardiovascular and gastrointestinal risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug (...) , diarrhoea, oedema, dry mouth, rash, dizziness, headache, and tiredness. 58-60 COX-2 selective NSAIDs had fewer side effects than traditional NSAIDs (RR 0.83, 95% CI 0.70 to 0.99). 58 Gastrointestinal (GI) adverse effects are well-established risks of long-term regular NSAID treatment. This has been compounded by emerging evidence showing an increased risk of cardiovascular disease, stroke and heart failure. The risk of serious upper GI events differs significantly between NSAIDs. 61 The greatest risk

2013 SIGN

664. The SIGN discharge document

Notes 10 Secondary discharge diagnosis/es y y secondary diagnosis/es y y confirmed or provisional y y code(s) Record any secondary diagnosis/es relevant to this admission. Include any relevant comorbidities that could have contributed to or be affected by the primary diagnosis (eg, hypertension in a patient admitted for stroke). y y Avoid acronyms, eg, ‘PvD’ , and abbreviations, as these may not be understood by the recipients, including patients. y y State whether each diagnosis is confirmed (...) Royal Hospital, Larbert Mr Douglas Gentleman Specialty Adviser for Rehabilitation Medicine, Scottish Medical and Scientific Advisory Committee and SGHSCD Specialty Adviser Ms Shelley Gray Director of Policy and Communications, Long Term Conditions Alliance Scotland Dr Anne Hendry National Clinical Lead for Quality, The Scottish Government Dr Richard Herriot Consultant Immunologist, Aberdeen Royal Infirmary Dr Liz Junor Consultant Clinical Oncologist, Edinburgh Cancer Centre, Western General Hospital

2012 SIGN

665. Antithrombotics: indications and management

Thrombolytic therapy 32 11 Cerebrovascular disease 34 11.1 Acute prophylaxis of further vascular events 34 11.2 Secondary prevention after acute ischaemic stroke or transient cerebral ischaemic attack 36 11.3 Carotid endarterectomy 36 12 Myeloproliferative disorders 37 13 Other indications for anticoagulant therapy 38 13.1 Disseminated intravascular coagulation 38 13.2 Acute promyelocytic leukaemia 38 14 Intravascular devices 39 14.1 Prevention of dvt due to central venous catheters 39 14.2 Treatment (...) or transient ischaemic attack) score has been validated and is used widely. 124, 125 It assigns two points for a history of ischaemic stroke or TIA and one for each of age 75 years and over, recent congestive heart failure, hypertension and diabetes mellitus (see Table 2) Table 2: CHADS 2 scheme for assessment of stroke risk in patients with non-valvular AF Calculation of CHADS 2 score Interpretation of stroke risk CHADS 2 risk factor Score Risk CHADS 2 score Annual stroke rate (%) Heart failure 1 LOW 0

2012 SIGN

666. SCAI Expert Consensus Statement: 2016 Best Practices in the Cardiac Catheterization Laboratory

of care because they shift the focus to per- formance measures that are not necessarily relevant to the CCL. Accordingly, directives were tailored to the percutaneous setting in order to assure quality and opti- mal patient safety while maintaining efficiency. 1 Division of Cardiology, Winthrop University Hospital, Mineola, New York 2 Warren Alpert Medical School of Brown University, Cardio- vascular Institute, Providence, RI 3 West Valley Medical Center, Caldwell, ID 4 FirstHealth of the Carolinas (...) /XML_Signal_Tmp_AA/JW-CCD#160133This clinical expert consensus statement pertains to diagnostic and therapeutic coronary artery procedures. Given the variety of practice settings in which periph- eral vascular procedures are being performed, and the more nascent field of structural heart interventions, which have their own expert consensus statements, a discussion of noncoronary artery procedures is beyond the scope of this document. The purpose of this docu- ment is not to represent all acceptable practices

2016 Society for Cardiovascular Angiography and Interventions

667. 2012 ACCF/SCAI Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update

. Major Adverse Cardiac or Cerebrovascular Events xxxx 3.2.1.1. PCI IN THE SETTING OF ST-ELEVATION MYOCARDIAL INFARCTION xxxx 3.2.2. Ad Hoc PCI Issues xxxx 3.3. Peripheral Vascular Intervention xxxx 3.4. Peer Review Continuous QA/QI Program xxxx 3.4.1. Overview of the Peer Review Process: Quality Indicators, Data Collection and Analysis, and QA/QI Interventions xxxx 3.4.2. Noncardiologists Performing Cardiac Catheterization xxxx 3.4.3. National Database Use xxxx 3.4.4. Catheterization Laboratory (...) a multipurpose suite with both diagnostic procedures to investigate pulmonary hyperten- sion and coronary ?ow and with therapeutic procedures that now include intervention into the cerebral and peripheral vascular systems as well as in structural heart disease. These new procedures have impacted both the adult and pediatric catheterization laboratories. The approaches now available allow for the treatment of even very complex heart disease and have led to the development of hybrid cardiac cathe- terization

2012 Society for Cardiovascular Angiography and Interventions

Guidelines

Guidelines – filter by country